Table 2 Outcomes of randomized trials comparing DOACs and dalteparin in the treatment of CAT

Recurrent VTE, n (%)

32 (5.6)

46 (7.9)

1 (0.7)

9 (6.3)

41 (7.9)

59 (11.3)

8 (4.0)^d

18 (11.0)^d

 HR (95% CI)^c

0.63 (0.37–1.07)

0.099 (0.013–0.78)

0.71 (0.48–1.06)

0.43 (0.19–0.99)

Major bleeding, n (%)

22 (3.8)

23 (4.0)

0

2 (1.4)

36 (6.9)

21 (4.0)

11 (6.0)^d

6 (4.0)^d

 HR (95% CI)^c

0.82 (0.40–1.69)

0.0 (0.0–)

1.77 (1.03–3.04)

1.83 (3–11)

Major GI bleeding, n (%)

11 (1.9)

10 (1.7)

0

0

20 (3.8)

6 (1.1)

8 (3.9)

4 (2.0)

 HR (95% CI)^c

1.05 (0.44–2.50)

NE

NR

NR

CRNM bleeding, n (%)

52 (9.0)

35 (6.0)

9 (6.2)

7 (4.2)

76 (14.6)

58 (11.1)

25 (13.0)^d

7 (4.0)^d

 HR (95% CI)^c

1.42 (0.88–2.30)

NR

1.38 (0.98–1.94)

3.76 (1.63–8.69)

Mortality, n (%)

135 (23.4)

153 (26.4)

23 (16)

15 (11)

206 (39.5)

192 (36.6)

48 (23.6)

56 (27.6)

 HR (95% CI)^c

0.82 (0.62–1.09)

1.40 (0.82–2.43)

1.12 (0.92–1.37)

NR